Immuuntherapie bij reumatoïde artritis; huidige stand van zaken

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 24, 1996, Pages 1255-1259

  Breedveld, F C ^a   Van De Putte, L B A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LONG TERM CARE; METHODOLOGY; REVIEW; RHEUMATOID ARTHRITIS; AUTOIMMUNITY; ETIOLOGY; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOTHERAPY; LONG-TERM CARE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030585626     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Panayi GS, Lanchbury JS, Kingsley GW. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
2. Pitzalis C, Kingsley G, Lanchbury JS, Murphy J, Panayi GS. Expression of HLA-DR, DQ and DP antigens and IL-2 R on synovial fluid T lymphocyte subsets in rheumatoid arthritis: evidence for 'frustrated' activation. J Rheumatol 1987;14:662-6.
3. Res PCM, Struijk L, Leow A, Daha MR, Elsen PC van den. Breedveld FC. Inflamed joints of patients with rheumatoid arthritis contain T cells that display in vitro proliferation to antigens present in autologous synovial fluid. Functional analysis on the basis of synovial-fluid-reactive T-cell clones and lines. Hum Immunol 1994;40: 291-8.
4. Struyk L, Hawes GE, Chatila MK, Breedveld FC, Kurnick JT, Elsen PJ van den. T cell receptors in rheumatoid arthritis. Arthritis Rheum 1995;38:577-89.
5. Zeben D van, Hazes JMW, Zwinderman AH, Cats A, Schreuder GM, D'Amoro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991;34:822-30.
6. Strober S, Tanay A, Field E, Hoppe RT, Calin A, Engleman EG, et al. Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial. Ann Intern Med 1985; 102:441-9.
7. Broek MF van den, Berg WB van den. Putte LBA van de. Monoclonal anti-Ia antibodies suppress the flare up reaction of antigen induced arthritis in mice. Clin Exp Immunol 1986;66:320-30.
8. Reiter C, Kakavand B, Richer EP, Schattenkirchner M, Riethmüller G, Krüger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 1991;34:625-36.
9. Lubbe PA van der, Reiter C, Breedveld FC, Krüger K, Schattenkirchner M, Sanders ME, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;36:1375-9.
10. Moreland L, Pratt P, Mayes M, Postlethwaite A. Weisman M, Schnitzer T, et al. Minimal efficacy of a depleting chimeric anti-CD4 (CM-T412) in treatment of patients with refractory rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX). Arthritis Rheum 1993;36:S39.
11. Lubbe PA van der, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
12. Tak PP, Lubbe PA van der, Breedveld FC, Lubbe PA van der, Cauli A, Daha MR, et al. Reduction of synovial inflammation after antiCD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
13. Weinblatt ME, Coblyn J, Maier A, Anderson R, Helfgott S, Thurmond L, et al. Continued lymphocyte suppression following single dose mAb therapy with CAMPATH 1 H: a 20 month follow up. Arthritis Rheum 1994;37:S420.
14. Strand V, Lipsky PE, Cannon GW, Calabrese LH, Wiesenhutter C, Cohen SB, et al. Effects of administration of an anti-CD5 immunoconjugate in rheumatoid arthritis. Results of two phase II studies. Arthritis Rheum 1993;36:620-30.
15. Moreland LW, Sewell KL, Sullivan WF, Shemerling RH, Parker KC, Swartz WG, et al. Double blind placebo controlled phase II trial of diphteria interleukin-2 fusion toxin (DAB 486 IL-2) in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993;36:S39.
16. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
17. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 1990;33:768-73.
18. Lent PLEM van, Berssellaar L van den, Hoek AEM van den, Ende LBA van de, Berg WB van den. Reversible depletion of synovial lining cells after intra articular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheumatol Int 1993;13:21-30.
19. Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, et al. TNF-alpha in rheumatoid arthritis and prospects of antiTNF therapy. Clin Exp Rheumatol 1993;11 Suppl 8:S173-5.
20. Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS, Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992;89:244-50.
21. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
22. Moreland LW, Margolies GR, Heck IW, Saway PA, Jacobs C, Beck C, et al. Soluble tumor necrosis factor receptor (sTNFR). Results of a phase 1 dose-escalation study in patients with rheumatoid arthritis. Arthritis Rheum 1994;37:S295.
23. Arend WP, Joslin FG, Thompson RC, Hannum CH, An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J Immunol 1989:142:1851-8.
24. Lebsack ME, Paul CC, Martindale JJ, Catalano AA. A dose regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1993;36:S39.
25. Kavanaugh AF, Davis LS, Nichols LE, Norris SH, Rothlein R, Scharschmidt LA, el al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.
26. Tak PP, Taylor PC, Breedveld FC, Macfarlane JD, Smeets TJM, Daha MR, et al. Infiltrate analysis of rheumatoid synovial tissue before and after anti-TNFα monoclonal antibody treatment [abstract]. Arthritis Rheum 1995;38:S185.
27. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727-30.
28. Breedveld FC, Struyk L, Laar JM van, Miltenburg AMM, Vries RRP de, Eisen PJ van den. Therapeutic regulation of T cells in rheumatoid arthritis. Immunol Rev 1995;144:5-16.
29. Elliolt MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, el al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
30. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-51.